4202:TSEDaicel Corporation Analysis
Data as of 2026-03-15 - not real-time
¥1,386.50
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Daicel’s share price of ¥1,386.5 sits just above the 20‑day SMA (¥1,548) and comfortably above the 50‑day SMA, indicating a short‑term pull‑back within a broader bullish framework. The stock is trading near its calculated support at ¥1,378 and below the 200‑day SMA, while the RSI of ~34 suggests oversold momentum that could spark a bounce. Although the MACD histogram remains negative and the signal line is bearish, volume is increasing, which often precedes a reversal when price is near support. On the fundamentals side, the company trades at a PE of ~10× (forward PE ~6×), a PB of ~0.93, and delivers a 4.33% dividend yield with a payout ratio under 45%, indicating attractive valuation and dividend sustainability. Low beta (0.32‑0.47) points to limited market‑wide volatility, though 30‑day volatility is elevated at roughly 37%. The specialty chemicals sector carries medium cyclical risk, while regulatory exposure is moderate given the chemical product mix. Overall, the confluence of a near‑term technical bounce potential, solid valuation cushions, and a reliable dividend makes Daicel a compelling candidate for investors seeking a blend of value and modest growth.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with oversold RSI
- Increasing volume indicating potential short‑term reversal
- MACD still bearish, suggesting caution
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued multiples (PE ~10x, forward PE ~6x)
- Sustainable dividend yield above 4%
- Improving earnings outlook (forward EPS > trailing EPS)
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong position in high‑growth specialty chemicals for electronics and healthcare
- Low beta and stable cash generation supporting dividend continuity
- Long‑term secular demand for performance plastics and safety components
Key Metrics & Analysis
Financial Health
Revenue Growth3.40%
Profit Margin7.11%
P/E Ratio10.2
ROE10.63%
ROA3.60%
Debt/Equity79.44
P/B Ratio0.9
Technical Analysis
TrendBullish
RSI34.0
Support¥1,378.00
Resistance¥1,658.00
MA 20¥1,548.43
MA 50¥1,504.25
MA 200¥1,352.42
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target Price¥1,515.00
Upside/Downside9.27%
GradeUndervalued
TypeValue
Dividend Yield4.33%
Risk Assessment
Beta0.47
Volatility36.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.